Biofortuna have signed a long-term contract to provide contract research and development to a leading early cancer detection company. This relationship will lead to the commercialisation of an ELISA based oncology assay.
Biofortuna will be providing:
Design and development consultancy of immunoassay technologies.
Expertise in ELISA reaction stabilisation methods.
Full validation and verification testing.
Technology transfer of small scale manufacturing procedures to full-scale commercialisation manufacturing protocols.
A potential manufacturing partner with a thorough understanding of the underlying technologies.
The client is now routinely manufacturing with Biofortuna to satisfy increased demand of its CE-marked kits.
